Janssen Research & Development, part of Johnson & Johnson, announced the formation of a global cross-pharmaceutical Investigator Databank to improve efficiencies of industry-sponsored clinical trials. Merck & Co. and Eli Lilly are the first two companies to join Janssen in this effort. The creation of the Investigator Databank follows the launch of TransCelerate BioPharma earlier this year, another industry collaboration formed to address challenges in drug development.
The new Investigator Databank is designed to be a one-stop repository where key information about clinical-trial sites, such as infrastructure and good clinical practice (GCP) training records, are housed. The aim is facilitate participating pharmaceutical companies to reduce time-consuming and sometimes redundant administrative work involved in identifying appropriate clinical-trial sites. At the outset of clinical trials, pharmaceutical companies initiate clinical-trial site selection, prequalification and GCP training, which can be paperwork-heavy and time-consuming for trial sponsors and investigators. By housing crucial information about investigators and trial sites in one place, the databank is designed to reduce time, cost, and duplicative efforts to make it easier for companies to identify appropriate trial sites and investigators for future clinical trials. Investigator sites that have opted-in to data-sharing will have their relevant information accessible to pharmaceutical companies participating in the collaboration. This databank will not include any patient data.